Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate

Journal of Laryngology and Otology

Volumn 118, Issue 11, 2004, Pages 866-871

  Patel, Rajan S ^a,c   Shaw, Steve R ^b   Wallace, A Michael ^a   McGarry, Gerald W ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c 23 Custom House ^*  (United Kingdom)

Author keywords

Adrenal Gland Hypofunction; Disease Management; Hypersensitivity; Saliva; Sensitivity and Specificity; Steroids; Toxicity Tests

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; HYDROCORTISONE; MOMETASONE FUROATE;

ADOLESCENT; ADRENAL DISEASE; ADRENAL SUPPRESSION; ADULT; AGED; ALLERGIC DISEASE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOSINUSITIS; SALIVA ANALYSIS;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; AGED; AMBULATORY CARE; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PREGNADIENEDIOLS; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; SALIVA; SENSITIVITY AND SPECIFICITY; SINUSITIS; TREATMENT OUTCOME;

EID: 10644282127     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/0022215042703769     Document Type: Article

References (24)

1. Bong JL, Connell JM, Lever R. Intranasal betamethasone induced acne and adrenal suppression. Br J Dermatol 2000;142:579-80
2. Findlay CA, Macdonald JF, Wallace AM, Geddes N, Donaldson MD. Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions. BMJ 1998;317:739-40
3. Flynn MD, Beasley P, Tooke JE. Adrenal suppression with intranasal betamethasone drops. J Laryngol Otol 1992;106:827-8
4. Gazis AG, Homer JJ, Henson DB, Page SR, Jones NS. The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clinical Otolaryngplogy & Allied Sciences 1999;24:495-8
5. Gill G, Swift A, Jones A, Strain D, Weston P. Severe adrenal suppression by steroid nasal drops. J R Soc Med 2001;94:350-1
6. Nutting CM, Page SR. Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at. Postgrad Med J 1995;71:231-2
7. Stevens DJ. Cushing's syndrome due to the abuse of betamethasone nasal drops. J Laryngol Otol 1988;102:219-21
8. Kimmerle R, Rolla AR. Iatrogenic Cushing's syndrome due to dexamethasone nasal drops. Am J Med 1985;79:535-7
9. Committee on Safety of Medicines and the Medicines Control Agency. Safety of inhaled and nasal corticosteroids. FOCUS on corticosteroids. Current Problems in Pharmacovigilance 1998;4:8-9
10. Patel RS, Wallace AM, Hinnie J, McGarry GW. Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops. Clin Otolaryngol 2001;26:231-4
11. Patel RS, McGarry GW. Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required. J Laryngol Otol 2001;115:633-5
12. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000;106(Suppl 4):S179-S190
13. Bronsky EA, Aaronson DW, Berkowitz RB, Chervinsky P, Graft D, Kaiser HB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:51-6
14. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997;19:27-38
15. Drouin M, Yang WH, Bertrand B, Van Cauwenberge P, Clement P, Dalby K, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153-60
16. Graft D, Aaronson D, Chervinsky P, Kaiser K, Melamed J, Pedinoff A, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98:724-31
17. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51:569-76
18. Wirth MA. Disposition of radiolabelled mometasone furoate in the mouse, rat and dog after oral and intravenous administration. International Society for the Study of Xenbiotics Proceedings 1995;8:275 [Abstract]
19. Zbaida S, Shannon D, Du Y. In vitro metabolism of mometasone furoate. FASEB J 1997;11:339 [Abstract]
20. Brannan MD, Seilberling M, Cutler D, Cuss F, Affrime MB. Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol 1996;97:198 [Abstract]
21. Lund V. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy 1994;49(Suppl 19):1-34
22. Benninger MS, Senior BA. The development of the Rhinosinusitis Disability Index. Arch Otolaryngol Head Neck Surg 1997;123:1175-9
23. Mygind N. Glucocorticosteroids and rhinitis. Allergy 1993;48:476-90
24. Ammari F, Issa BG, Millward E, Scanion MF. A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Clin Endocrinol (Oxf) 1996;44:473-6